Literature DB >> 10898707

Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan.

M Kato1, Y Yamaoka, J J Kim, R Reddy, M Asaka, K Kashima, M S Osato, F A El-Zaatari, D Y Graham, D H Kwon.   

Abstract

The patterns of antibiotic resistance in Helicobacter pylori were assessed in two different regions in Japan. Overall, prevalences of resistance to metronidazole and clarithromycin were 12.4 and 12.9%, respectively. While there was no difference in clarithromycin resistance, the prevalence of metronidazole resistance was significantly higher in Kyoto (23.8%) than in Sapporo (8.1%). From 1996 to 1999, the prevalence of metronidazole resistance did not change but the prevalence of clarithromycin resistance doubled (from 9.1 to 18.7%).

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10898707      PMCID： PMC90045          DOI： 10.1128/AAC.44.8.2214-2216.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

Review 1.  Helicobacter pylori infection in the pathogenesis of duodenal ulcer and gastric cancer: a model.

Authors:  D Y Graham
Journal:  Gastroenterology       Date:  1997-12       Impact factor: 22.682

2.  The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance.

Authors:  H Seppälä; T Klaukka; J Vuopio-Varkila; A Muotiala; H Helenius; K Lager; P Huovinen
Journal:  N Engl J Med       Date:  1997-08-14       Impact factor: 91.245

3.  Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study.

Authors:  F Mégraud; N Lehn; T Lind; E Bayerdörffer; C O'Morain; R Spiller; P Unge; S V van Zanten; M Wrangstadh; C F Burman
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

Review 4.  Helicobacter pylori: current status.

Authors:  D Y Graham; M F Go
Journal:  Gastroenterology       Date:  1993-07       Impact factor: 22.682

Review 5.  NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease.

Authors: 
Journal:  JAMA       Date:  1994-07-06       Impact factor: 56.272

6.  Metronidazole and clarithromycin resistance amongst Helicobacter pylori isolates from a large metropolitan hospital in the United States.

Authors:  M S Osato; R Reddy; D Y Graham
Journal:  Int J Antimicrob Agents       Date:  1999-08       Impact factor: 5.283

7.  Metronidazole and clarithromycin resistance in Helicobacter pylori determined by measuring MICs of antimicrobial agents in color indicator egg yolk agar in a miniwell format. The Gastrointestinal Physiology Working Group of Universidad Peruana Cayetano Heredia and the Johns Hopkins University.

Authors:  A Vasquez; Y Valdez; R H Gilman; J J McDonald; T U Westblom; D Berg; H Mayta; V Gutierrez
Journal:  J Clin Microbiol       Date:  1996-05       Impact factor: 5.948

8.  Prevalence of primary Helicobacter pylori resistance to metronidazole and clarithromycin in The Netherlands.

Authors:  A A van Zwet; W A de Boer; P M Schneeberger; J Weel; A R Jansz; J C Thijs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-11       Impact factor: 3.267

9.  Results of a multicentre European survey in 1991 of metronidazole resistance in Helicobacter pylori. European Study Group on Antibiotic Susceptibility of Helicobacter pylori.

Authors: 
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-09       Impact factor: 3.267

Review 10.  The treatment of Helicobacter pylori infection in the management of peptic ulcer disease.

Authors:  J H Walsh; W L Peterson
Journal:  N Engl J Med       Date:  1995-10-12       Impact factor: 91.245
View more
  23 in total

Review 1.  H pylori antibiotic resistance: prevalence, importance, and advances in testing.

Authors:  F Mégraud
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

2.  Phenotypic and genotypic analysis of clarithromycin-resistant Helicobacter pylori from Bogotá D.C., Colombia.

Authors:  Alba A Trespalacios; William Otero; Jorge E Caminos; Marcela M Mercado; Jenny Avila; Liliana E Rosero; Azucena Arévalo; Raúl A Poutou-Piñales; David Y Graham
Journal:  J Microbiol       Date:  2013-08-30       Impact factor: 3.422

3.  Helicobacter pylori and antibiotic resistance.

Authors:  Francis Megraud
Journal:  Gut       Date:  2007-11       Impact factor: 23.059

Review 4.  Second and third line treatment options for Helicobacter pylori eradication.

Authors:  Mingjun Song; Tiing Leong Ang
Journal:  World J Gastroenterol       Date:  2014-02-14       Impact factor: 5.742

5.  Dynamics of Helicobacter pylori-specific immunoglobulin G for 2 years after successful eradication of Helicobacter pylori infection in an American Indian and Alaska Native population.

Authors:  Karen M Miernyk; Dana L Bruden; Michael G Bruce; Brian J McMahon; Thomas W Hennessy; Helen V Peters; Debby A Hurlburt; Frank Sacco; Alan J Parkinson
Journal:  Clin Vaccine Immunol       Date:  2006-11-01

6.  Effect of glycine on Helicobacter pylori in vitro.

Authors:  Masaaki Minami; Takafumi Ando; Shin-Nosuke Hashikawa; Keizo Torii; Tadao Hasegawa; Dawn A Israel; Kenji Ina; Kazuo Kusugami; Hidemi Goto; Michio Ohta
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

7.  Efficacy of two triple eradication regimens in children with Helicobacter pylori infection.

Authors:  Jungi Choi; Joo Young Jang; Joon Sung Kim; Hwa Young Park; Yon Ho Choe; Kyung Mo Kim
Journal:  J Korean Med Sci       Date:  2006-12       Impact factor: 2.153

8.  Generation of Helicobacter pylori ghosts by PhiX protein E-mediated inactivation and their evaluation as vaccine candidates.

Authors:  Klaus Panthel; Wolfgang Jechlinger; Alexander Matis; Manfred Rohde; Michael Szostak; Werner Lubitz; Rainer Haas
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

9.  High level of resistance to metronidazole and clarithromycin in Helicobacter pylori isolated from pediatric patients in Poland (1997-2001).

Authors:  G Gościniak; B Iwańczak; A Przondo-Mordarska; J Grabińska; F Iwańczak
Journal:  Folia Microbiol (Praha)       Date:  2004       Impact factor: 2.099

10.  Colonization of C57BL/6J and BALB/c wild-type and knockout mice with Helicobacter pylori: effect of vaccination and implications for innate and acquired immunity.

Authors:  Klaus Panthel; Gerhard Faller; Rainer Haas
Journal:  Infect Immun       Date:  2003-02       Impact factor: 3.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.